2023
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain K, Pusztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226. Journal Of Clinical Oncology 2023, 41: 1076-1076. DOI: 10.1200/jco.2023.41.16_suppl.1076.Peer-Reviewed Original ResearchProgression-free survivalMetastatic breast cancerThymidine kinase 1 activityHormone receptor-positive metastatic breast cancerPositive metastatic breast cancerOverall survivalEndocrine therapyCA 15Breast cancerCA15-3Predictors of PFSFirst-line endocrine therapySubsequent progression-free survivalWorse progression-free survivalSerum thymidine kinase 1Systemic endocrine therapyMultivariable Cox modelCox regression analysisWorse overall survivalHypothesis-generating dataCycles of treatmentTamoxifen useSystemic therapySerum levelsMultivariable analysis
2018
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L. An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal Of Cancer 2018, 118: 1107-1114. PMID: 29559730, PMCID: PMC5931099, DOI: 10.1038/s41416-018-0030-0.Peer-Reviewed Original ResearchConceptsHER2-negative tumorsBreast cancer patientsCancer patientsER-positive/HER2-negative tumorsBreast cancer molecular subtypesMETABRIC data setMolecular breast cancer subtypesCox regression analysisBreast cancer subtypesCancer molecular subtypesGene expression profilesMann-Whitney U testRegression analysisMultivariate regression analysisPrognostic valueKaplan-MeierBreast cancerClinical dataDisease outcomeTCGA cohortGene expressionMolecular subtypesCancer-associated genesCancer-related genesClinical relevance
2012
Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment.
Symmans W, Andreopoulou E, Booser D, Hatzis C, Wallace M, Zhang Y, Gong Y, Ignatiadis M, Sotiriou C, Andre F, Peintinger F, Regitnig P, Marth C, Desmedt C, Loi S, Moulder S, Hortobagyi G, Pusztai L, Valero V. Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. Journal Of Clinical Oncology 2012, 30: 515-515. DOI: 10.1200/jco.2012.30.15_suppl.515.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalBreast cancerHormonal therapyStage IIBStage IIIMetastatic estrogen receptor-positive breast cancerStage IVGenomic subtypesEstrogen receptor-positive breast cancerStage progressionReceptor-positive breast cancerPalliative hormonal therapyAJCC stage ICox regression analysisHigh-risk subtypesClinical progressionStage IIARisk subtypesBiopsy samplesStage IStaging methodMBC samplesTreatment typeCancer
2007
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal Of Clinical Oncology 2007, 25: 4414-4422. PMID: 17785706, DOI: 10.1200/jco.2007.10.6823.Peer-Reviewed Original ResearchConceptsDistant relapse-free survivalResidual cancer burdenHormone receptor statusNeoadjuvant chemotherapyHormone therapyPathologic responseReceptor statusCancer burdenResidual diseasePathologic American Joint CommitteeMultivariate Cox regression analysisAdjuvant hormone therapyBreast cancer burdenDifferent treatment cohortsPretreatment clinical stageAmerican Joint CommitteeCox regression analysisRelapse-free survivalSequential paclitaxelDistant relapseSame prognosisComplete responseNodal metastasisTreatment cohortsClinical stageInclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
Mazouni C, Kau S, Frye D, Andre F, Kuerer H, Buchholz T, Symmans W, Anderson K, Hess K, Gonzalez-Angulo A, Hortobagyi G, Buzdar A, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals Of Oncology 2007, 18: 874-880. PMID: 17293601, DOI: 10.1093/annonc/mdm008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsBridged-Ring CompoundsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisReceptors, EstrogenSurvival AnalysisTaxoidsTumor BurdenConceptsPathologic complete response rateComplete response rateER-negative tumorsPreoperative chemotherapyPCR rateER statusBreast cancerResponse rateEstrogen receptor-positive breast cancerReceptor-positive breast cancerMD Anderson Cancer CenterBreast cancer benefitER-negative statusInclusion of taxanesER-negative patientsER-positive patientsER-positive tumorsNeo-adjuvant therapyType of regimenClinical tumor sizeSubset of patientsCox regression analysisER-negative cancersPositive breast cancerAnderson Cancer Center
2006
A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy
Symmans W, Peintinger F, Hatzis C, Kuerer H, Valero V, Hennessy B, Green M, Singletary E, Hortobagyi G, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2006, 24: 536-536. DOI: 10.1200/jco.2006.24.18_suppl.536.Peer-Reviewed Original ResearchDistant relapse-free survivalResidual cancer burdenPathologic complete responseResidual diseaseComplete responsePathologic responseAJCC stageCancer burdenMultivariate Cox regression analysisRCB-3AJCC stage IIIHigh-risk patientsCox regression analysisNeoadjuvant chemotherapy trialsRelapse-free survivalDifferent prognostic groupsMedian followNeoadjuvant trialsPaclitaxel scheduleWeekly paclitaxelChemotherapy trialsNeoadjuvant chemotherapyPCR rateStrength of associationSurvival benefit
2004
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy
Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2004, 59: 1337-1342. PMID: 15275718, DOI: 10.1016/j.ijrobp.2004.02.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibiotics, AntineoplasticBreast NeoplasmsChemotherapy, AdjuvantClinical Trials as TopicConfidence IntervalsDoxorubicinDrug Resistance, NeoplasmFemaleHumansLymphatic MetastasisMastectomy, RadicalNeoadjuvant TherapyNeoplasm ProteinsNeoplasm Recurrence, LocalRadiation ToleranceReceptor, ErbB-2Receptors, EstrogenRegression AnalysisRetrospective StudiesConceptsHER2/neu-positive diseaseHER2/neu-positive tumorsLocoregional recurrenceHER2/neuNeoadjuvant doxorubicinHER2/neu-negative diseaseHER2/neu-negative tumorsEstrogen receptor-negative diseaseHER2/neu positivityHER2/neu overexpressionChest wall boostNeu-negative tumorsOverall LRR ratePositive lymph nodesReceptor-negative diseaseCox regression analysisEstrogen receptor statusLRR rateSupraclavicular diseaseHazard ratioLymph nodesReceptor statusPostmastectomy radiotherapyPreclinical dataNeu overexpression
2001
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy.
Buchholz T, Hill B, Tucker S, Frye D, Kuerer H, Buzdar A, McNeese M, Singletary S, Ueno N, Pusztai L, Valero V, Hortobagyi G. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. The Cancer Journal 2001, 7: 413-20. PMID: 11693900.Peer-Reviewed Original ResearchConceptsEstrogen receptor-negative diseaseReceptor-negative diseaseLocal-regional recurrenceLocal-regional recurrence ratePositive lymph nodesNeoadjuvant chemotherapyLymph nodesOverall survivalProgressive diseaseRecurrence rateLymph node-negative diseaseSignificant poorer overall survivalEstrogen receptor-positive diseaseBreast cancer refractoryInvolved lymph nodesNegative lymph nodesReceptor-positive diseaseNode-negative diseasePostoperative radiation therapyInitial clinical stageCox regression analysisBreast cancer patientsPoor overall survivalAdjuvant chemotherapyCancer refractory